Evidence map›Paper›PMID 31842282›Full record

ArticleMolecules (Basel, Switzerland)2019

The Meta-Position of Phe

Robert J Cassell, Krishna K Sharma, Hongyu Su, Benjamin R Cummins, Haoyue Cui, Kendall L Mores, Arryn T Blaine, Ryan A Altman, Richard M van Rijn

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Robert J CassellDepartment of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA.
Krishna K SharmaDepartment of Medicinal Chemistry, The University of Kansas, Lawrence, KS 66045, USA.ORCID 0000-0003-4927-745X
Hongyu SuDepartment of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA.
Benjamin R CumminsDepartment of Chemistry, Purdue University, West Lafayette, IN 47907, USA.
Haoyue CuiCollege of Wuya, Shenyang Pharmaceutical University, Shenyang 110016, China.
Kendall L MoresDepartment of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA.
Arryn T BlaineDepartment of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA.
Ryan A AltmanDepartment of Medicinal Chemistry, The University of Kansas, Lawrence, KS 66045, USA.ORCID 0000-0002-8724-1098
Richard M van RijnDepartment of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA.ORCID 0000-0002-9957-1633
Purdue University West Lafayette · USUniversity of Kansas · USShenyang Pharmaceutical University · CN

Funding

Mentoring CoreP20GM103418 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Douglas E Wright · 2012 to 2026
$63.0M
G-protein-, beta-arrestin- and ERK-signaling in alcohol use- and anxiety-disordersR01AA025368 · NIAAA · PURDUE UNIVERSITY · PI CHESTER, JULIA ANN · 2017 to 2021
$1.7M
Evaluation of Physicochemical Properties Imparted by Fluorinated PeptidomimeticsR33DA036730 · NIDA · UNIVERSITY OF KANSAS LAWRENCE · PI ALTMAN, RYAN A · 2017 to 2018
$706k
Opioidergic alkaloids from Mitragynia Speciosa (kratom) as novel treatment for alcohol use disorderR21AA026949 · NIAAA · PURDUE UNIVERSITY · PI VAN RIJN, RICHARD M. · 2018 to 2019
$421k
Evaluation of Physicochemical Properties Imparted by Fluorinated PeptidomimeticsR21DA036730 · NIDA · UNIVERSITY OF KANSAS LAWRENCE · PI ALTMAN, RYAN A · 2015 to 2016
$373k
The influence of alcohol on the metastatic dormancy of breast cancerR21AA026675 · NIAAA · PURDUE UNIVERSITY · PI VAN RIJN, RICHARD M., WENDT, MICHAEL KEITH · 2018 to 2019
$280k
Development of G-protein biased delta opioid receptor agonist with analgesic potencyR03DA045897 · NIDA · PURDUE UNIVERSITY · PI VAN RIJN, RICHARD M. · 2018 to 2019
$149k
Foundation for the National Institutes of Health P20GM103418Foundation for the National Institutes of Health S10OD016360Foundation for the National Institutes of Health S10RR024664National Science Foundation 0320648National Science Foundation 9977422NIAAA NIH HHS AA025368NIAAA NIH HHS AA026675NIAAA NIH HHS AA026949NIAAA NIH HHS R01 AA025368NIAAA NIH HHS R21 AA026949NIDA NIH HHS DA036730NIDA NIH HHS DA045897NIDA NIH HHS R03 DA045897NIDA NIH HHS R33 DA036730NIGMS NIH HHS P20 GM103418
6 · The paper itself

Abstract

As tool compounds to study cardiac ischemia, the endogenous δ-opioid receptors (δOR) agonist Leu

Indexed as

AnimalsCHO CellsCricetulusEnkephalin, LeucineHumansPhenylalanineReceptors, Opioid, deltaReceptors, Opioid, muSignal TransductionEnkephalin, LeucinePhenylalanineReceptors, Opioid, deltaReceptors, Opioid, mubeta-arrestinbiased signalingDADLEdelta opioid receptorischemiaLeu-enkephalinmu opioid receptorplasma stability

Identifiers

PMID31842282
PMCPMC6943441
OpenAlexW2994980888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.